The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer Institute.
from News Medical Medical Research News Feed https://ift.tt/2JVzsR8
0 Comments